A detailed history of Indie Asset Partners, LLC transactions in Amgen Inc stock. As of the latest transaction made, Indie Asset Partners, LLC holds 1,130 shares of AMGN stock, worth $298,873. This represents 0.28% of its overall portfolio holdings.

Number of Shares
1,130
Previous 1,128 0.18%
Holding current value
$298,873
Previous $352,000 3.41%
% of portfolio
0.28%
Previous 0.29%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 29, 2024

BUY
$309.38 - $337.38 $618 - $674
2 Added 0.18%
1,130 $364,000
Q2 2024

Aug 05, 2024

BUY
$262.75 - $319.31 $21,282 - $25,864
81 Added 7.74%
1,128 $352,000
Q1 2024

May 10, 2024

BUY
$268.87 - $324.56 $2,957 - $3,570
11 Added 1.06%
1,047 $297,000
Q4 2023

Jan 26, 2024

SELL
$255.7 - $288.46 $1,278 - $1,442
-5 Reduced 0.48%
1,036 $298,000
Q2 2023

Aug 07, 2023

SELL
$214.27 - $253.37 $1,499 - $1,773
-7 Reduced 0.67%
1,041 $231,000
Q2 2022

Aug 12, 2022

SELL
$230.71 - $256.74 $17,303 - $19,255
-75 Reduced 6.68%
1,048 $255,000
Q4 2021

Feb 11, 2022

SELL
$198.88 - $227.6 $43,554 - $49,844
-219 Reduced 16.32%
1,123 $253,000
Q3 2021

Nov 09, 2021

SELL
$212.27 - $248.7 $10,613 - $12,435
-50 Reduced 3.59%
1,342 $285,000
Q2 2021

Aug 11, 2021

SELL
$233.58 - $259.14 $53,723 - $59,602
-230 Reduced 14.18%
1,392 $339,000
Q4 2020

Feb 09, 2021

BUY
$216.38 - $257.67 $2,163 - $2,576
10 Added 0.62%
1,622 $373,000
Q2 2020

Aug 12, 2020

SELL
$197.81 - $242.74 $28,682 - $35,197
-145 Reduced 8.25%
1,612 $384,000
Q1 2020

May 13, 2020

SELL
$182.24 - $241.7 $18,224 - $24,170
-100 Reduced 5.39%
1,757 $356,000
Q4 2019

Feb 11, 2020

BUY
$189.21 - $243.2 $351,362 - $451,622
1,857 New
1,857 $448,000

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $141B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Indie Asset Partners, LLC Portfolio

Follow Indie Asset Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Indie Asset Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Indie Asset Partners, LLC with notifications on news.